<DOC>
	<DOCNO>NCT01019772</DOCNO>
	<brief_summary>The purpose study evaluate compare immunogenicity safety LBVH0101 ( Haemophilus influenzae type b tetanus toxoid conjugate vaccine ) Hiberix™ vaccination healthy infant 2 , 4 , 6 month age .</brief_summary>
	<brief_title>Immunogenicity Safety Study LBVH0101 Healthy Infants Two , Four Six Months Age</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female infant age 49 day 84 day time enrollment . The gestation period 37 week longer , birth weight 2.5 kg . The infant parents/legally acceptable representative could comply schedule visit study study requirement relate protocol compliance . The parents/legally acceptable representative ( LAR ) sign write consent form . Had previously receive Haemophilus influenzae type b vaccine prior clinical study . Had plan vaccination vaccine permit protocol base standard vaccination schedule . Had contact patient confirm Hib infection within 30 day study start . Had fever ≥ 37.5°C within last 3 day ( If measure tympanic thermometer , fever 38°C high ) Had suspect immune function disorder ; previously receive suspected receive immunosuppressive therapy ; receive immunosuppressive therapy within 30 day prior participate study ( include systemic corticosteroid inhalation corticosteroid ) ( However , exclusion criterion receive corticosteroid therapy ( prednisolone equivalent ≤ 0.5 mg/kg/day ) 14 consecutive day least 30 day participation study ) . Had receive treatment parenteral immunoglobulin blood product birth . Had allergic history consider due component vaccine include excipients preservative . Three precede generation ancestral line Korean heritage . Had suspect significant disorder blood , heart , liver , kidney , nervous system , respiratory system , digestive system , investigator decide evaluation study objective might interrupt . Had treat investigational drug participate another clinical trial within 30 day prior study entry , participate another clinical study time . Had plan move away area study site complete study . Inappropriate take part clinical study principal investigator subinvestigator 's opinion , reason criterion .</criteria>
	<gender>All</gender>
	<minimum_age>49 Days</minimum_age>
	<maximum_age>84 Days</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>